A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma

ClinicalTrials.gov ID

NCT07705308

Lead Sponsor

Ruijin HospitalOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

140Estimated

Last Update Posted

Jul 15, 2026Actual

Start Date

Aug 1, 2026Estimated

Primary Completion Date

Aug 1, 2028Estimated

Completion Date

May 1, 2031Estimated

Official Title

A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma

Brief Summary

Multi center, randomized, controlled, prospective clinical trial to explore the clinical efficacy and safety of low-dose radiotherapy combined with targeted therapy for localized MALT lymphoma.

• Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)

• Radiation (Very low dose)
• Radiation (Standard)

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Patients must meet all of the following criteria to be eligible for enrollment in this study:

• The patient voluntarily agrees to participate in this study and provides written informed consent;

• Age ≥ 18 years;

• Histopathologically confirmed diagnosis of extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) type;

• Involved sites include but are not limited to: orbit, parotid gland, thyroid, Helicobacter pylori (H. pylori)-negative gastric MALT (in this study, H. pylori-negative gastric MALT is defined as negative results on both gastric mucosal tissue biopsy and serum H. pylori antibody test within the past 6 months; for patients with unknown prior H. pylori status who have received anti-H. pylori therapy, a positive serum H. pylori antibody test is permissible, provided that a subsequent gastroscopy or urea breath test confirms negativity);

• Lugano stage I-II disease;

• Able to swallow tablets normally;

• Eastern Cooperative Oncology Group performance status (ECOG-PS) score of 0-2;

• No prior radiotherapy, chemotherapy, targeted therapy, or immunotherapy for MALT lymphoma;

• Life expectancy ≥ 12 months;

• Adequate major organ function, meeting the following criteria:

  1. Hematological parameters: absolute neutrophil count ≥ 1.0 × 10⁹/L; platelet count ≥ 50 × 10⁹/L; hemoglobin ≥ 80 g/L;
  2. Biochemical parameters: total bilirubin < 1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN; serum creatinine ≤ 1.5 × ULN or calculated creatinine clearance > 50 mL/min;

• Female patients of childbearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose of study treatment and must agree to use highly effective methods of contraception during the study period and for 120 days after the last dose. Male patients with female partners of childbearing potential must be surgically sterile or agree to use highly effective methods of contraception during the study period and for 120 days after the last dose.

Exclusion Criteria:

• Patients who meet any of the following criteria will be excluded from enrollment in this study:
• Major surgery (excluding diagnostic surgery) within 4 weeks prior to enrollment;
• Previous or concurrent diagnosis of another malignancy, with the exception of adequately treated basal cell carcinoma of the skin, carcinoma in situ of the cervix, or carcinoma in situ of the breast;
• Active chronic hepatitis B infection, defined as detectable HBV DNA;
• Active HIV or syphilis infection;
• Presence of severe concomitant medical conditions or circumstances that may affect the patient's eligibility or safety during the study period;
• Pregnant or breastfeeding women;
• Presence of active psychiatric disorders or other psychological conditions that may impair the patient's ability to provide informed consent or understand the study procedures;
• Patients considered by the investigator to have poor compliance; Pathologically or radiologically confirmed distant metastasis; Other factors that, in the investigator's judgment, may affect the study results or necessitate premature termination of the study, including but not limited to alcohol abuse, drug abuse, other severe diseases (including psychiatric disorders) requiring concomitant treatment, significant laboratory abnormalities, or family/social circumstances that may compromise patient safety.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Single

Lead Sponsor

Ruijin HospitalOTHER

hou_yunhua@fudan.edu.cn+86-021-64923400

jiexianma@hotmail.com+86-021-62483180

• Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma

  NCT06583837

  Active, not recruitingInterventionalPhase 2Updated Feb 27, 2026
• Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma

  NCT07554898

  RecruitingInterventionalPhase 2Updated May 11, 2026
• Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL

  NCT07448324

  RecruitingInterventionalPhase 2Updated Mar 4, 2026
• Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma

  NCT07247383

  Active, not recruitingInterventionalPhase 2Updated Nov 25, 2025
• Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma

  NCT07355699

  RecruitingInterventionalPhase 4Updated Jan 21, 2026
• Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma

  NCT07022223

  RecruitingInterventionalPhase 2Updated Jun 15, 2025